Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025
Rhea-AI Summary
Alpha Cognition (NASDAQ: ACOG) reported accelerating 3Q25 commercialization of ZUNVEYL, driven by expansion in the U.S. long-term care channel. Pharmacy orders grew 102% sequentially, prescription volumes hit record monthly highs, and reach extended to >600 nursing homes with a prescriber base above 500 clinicians. Revenue for the quarter was $2.8M, comprising $2.3M of ZUNVEYL net product sales and $0.5M of licensing revenue. Pro forma cash after an October equity raise is about $73.2M, with a $75M ATM facility and roughly two years of runway at planned operating spend. Management continues to prioritize an LTC-focused call strategy to drive durable adoption and repeat ordering.
Positive
- Pharmacy orders +102% sequential growth
- Quarter revenue of $2.8M, including $2.3M net product sales
- Prescriber base exceeded 500 clinicians
- Pro forma cash ~ $73.2M after October equity raise
Negative
- Pro forma cash provides roughly two years of runway at planned spend
- Commercial revenue remains modest at $2.8M in 3Q25
News Market Reaction 3 Alerts
On the day this news was published, ACOG declined 3.10%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $118M at that time.
Data tracked by StockTitan Argus on the day of publication.
Dallas, Texas--(Newsfile Corp. - November 14, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition completed its second quarter of ZUNVEYL® commercialization in 3Q25, with launch momentum accelerating across the U.S. long-term care (LTC) channel. Pharmacy orders grew
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Revenue reached
$2.8M in the quarter, including$2.3M of ZUNVEYL net product sales and$0.5M in licensing revenue with strong sequential growth. - Pro forma cash is about
$73.2M after the October equity raise, providing roughly two years of runway at planned operating spend and supported by a$75M ATM facility. - ZUNVEYL launch momentum is building with more than 500 prescribers, coverage of over 600 nursing homes, and pharmacy orders more than doubling q/q.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274515
FAQ
How much revenue did Alpha Cognition (ACOG) report for 3Q25?
What portion of 3Q25 revenue was ZUNVEYL net product sales for ACOG?
How fast did pharmacy orders for ZUNVEYL grow in 3Q25 for ACOG?
How many prescribers and nursing homes does ACOG report for the ZUNVEYL launch?
What is Alpha Cognition's cash position and runway after the October equity raise?
Does Alpha Cognition have additional financing available beyond cash on hand?
